PD‑L1 gene expression in Japanese lung cancer patients

Sasaki,Hidefumi; Suzuki,Ayumi; Shitara,Masayuki; Hikosaka,Yu; Okuda,Katsuhiro; Moriyama,Satoru; Yano,Motoki; Fujii,Yoshitaka

doi:10.3892/br.2012.10

PD‑L1 gene expression in Japanese lung cancer patients

Authors:
- Hidefumi Sasaki
- Ayumi Suzuki
- Masayuki Shitara
- Yu Hikosaka
- Katsuhiro Okuda
- Satoru Moriyama
- Motoki Yano
- Yoshitaka Fujii
View Affiliations

Affiliations: Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya 467‑8601, Japan
Published online on: September 19, 2012 https://doi.org/10.3892/br.2012.10
Pages: 93-96

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

An imbalance in immune regulation affects tumor‑specific T‑cell immunity in the cancer microenvironment and reshapes tumor progression and metastasis. Blockade of interactions of immune function mediates antitumor activity in preclinical models. In the present study, we investigated programmed cell death 1 ligand 1 (PD-L1) mRNA expression by real-time polymerase chain reaction (RT‑PCR) using a LightCycler in surgically treated non‑small cell lung cancer (NSCLC) cases. This study included 123 surgically removed NSCLC cases for mRNA level analyses. The PD‑L1/β‑actin mRNA levels showed no marked difference in lung cancer (131.398±421.596) and adjacent normal lung tissues (78.182±254092, P=0.1482). The tumor/normal (T/N) ratio of PD‑L1/β‑actin mRNA levels was more than 2 in 49 cases and more than 1 in 63 cases. No difference was found in the T/N ratio of PD‑L1/β actin mRNA levels among factors inlcuding gender, age, smoking status and pathological subtypes. The T/N ratio of PD‑L1/β actin mRNA levels was markedly higher in pathological T4 cases (15.811±36.883) compared to T1 cases (3.492±8.494, P=0.0235). However, the PD‑L1 mRNA status did not correlate with lymph node metastasis status. Thus, PD‑L1 may drive tumor invasion, while providing a candidate for blockade of its function as a strategy to antagonize the progression process in NSCLC.

View Figures

View References

1.	Ginsberg RJ, Kris MK and Armstrong G: Cancer of the lung. Principles and Practice of Oncology. 4th edition. Lippincott; Philadelphia: pp. 673–682. 1993
2.	Sakata R, Fujii Y and Kuwano H: Thoracic and cardiovascular surgery in Japan during 2009: annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 59:636–667. 2011. View Article : Google Scholar : PubMed/NCBI
3.	Postmus PE: Chemotherapy for non-small cell lung cancer: the experience of the Lung Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. Chest. 113:28S–31S. 1998. View Article : Google Scholar : PubMed/NCBI
4.	Zou W: Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Rev Cancer. 5:263–274. 2005. View Article : Google Scholar : PubMed/NCBI
5.	Chen L, Linsley PS and Hellstrom KE: Costimulation of T cells for tumor immunity. Immunol Today. 14:483–486. 1993. View Article : Google Scholar : PubMed/NCBI
6.	Boise LH, Noel PJ and Thompson CB: CD28 and apoptosis. Curr Opin Immunol. 7:620–625. 1995. View Article : Google Scholar : PubMed/NCBI
7.	Watts TH and DeBenedette MA: T cell co-stimulatory molecules other than CD28. Curr Opin Immunol. 11:286–293. 1999. View Article : Google Scholar : PubMed/NCBI
8.	Dong H, Strome SE, Salomao DR, et al: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
9.	Iwai Y, Ishida M, Tanaka Y, et al: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 99:12293–12297. 2002. View Article : Google Scholar : PubMed/NCBI
10.	Zou W and Chen L: Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 8:467–477. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
12.	Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
13.	Wittwer CT, Ririe KM, Andrew RV, et al: The LightCycler: a microvolume multi sample fluorimeter with rapid temperature control. Biotechniques. 22:176–181. 1997.PubMed/NCBI
14.	Sjoblom T, Jones S, Wood LD, et al: The consensus coding sequences of human breast and colorectal cancers. Science. 314:268–274. 2006. View Article : Google Scholar : PubMed/NCBI
15.	Topalian SL, Weiner GJ and Pardoll DM: Cancer immunotherapy comes of age. J Clin Oncol. 29:4828–4836. 2011. View Article : Google Scholar : PubMed/NCBI
16.	Mellman I, Coukos G and Dranoff G: Cancer immunotherapy comes of age. Nature. 480:480–489. 2011. View Article : Google Scholar : PubMed/NCBI
17.	Drake CG, Jaffee E and Pardoll DM: Mechanisms of immune evasion by tumors. Adv Immunol. 90:51–81. 2006. View Article : Google Scholar : PubMed/NCBI
18.	Mizoguchi H, O’Shea JJ, Longo DL, et al: Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science. 258:1795–1598. 1792. View Article : Google Scholar : PubMed/NCBI
19.	Hodi FS, O’Day SJ, McDermott DF, et al: Improves survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar
20.	Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 364:2517–2526. 2011. View Article : Google Scholar : PubMed/NCBI
21.	Dong H, Zhu G, Tamada K and Chen L: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 5:1365–1369. 1999. View Article : Google Scholar : PubMed/NCBI
22.	Freeman GJ, Long AJ, Iwai Y, et al: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 192:1027–1034. 2000. View Article : Google Scholar : PubMed/NCBI
23.	Topalian SL, Drake CG and Pardoll DM: Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 24:207–212. 2012. View Article : Google Scholar : PubMed/NCBI
24.	Brahmer JR, Drake CG, Wollner I, et al: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 28:3167–3175. 2010. View Article : Google Scholar